Abstract:Background: In addition to being secreted into the intercellular spaces by exocytosis, insulin-like growth factor binding protein 5 (IGFBP5) may also remain in the cytosol or be transported to the nucleus. Depending on the different cellular context and subcellular distribution, IGFBP5 can act as a tumor suppressor or promoter through insulin-like growth factor -dependent or -independent mechanisms. Yet, little is known about the impacts of IGFBP5 on acute myeloid leukemia (AML) and its underlying mechanism. Methods: Here we investigated the roles of IGFBP5 in human AML by using recombinant human IGFBP5 (rhIGFBP5) protein and U937 and THP1 cell lines which stably and ectopically expressed IGFBP5 or mutant IGFBP5 (mtIGFBP5) with the lack of secretory signal peptide. Cell counting kit-8 and flow cytometry assay were conducted to assess the cell viability, cell apoptosis and cell cycle distribution. Cytotoxicity assay was used to detect the chemosensitivity. Leukemia xenograft model and hematoxylin-eosin staining were performed to evaluate AML progression and extramedullary infiltration in vivo. Results: In silico analysis demonstrated a positive association between IGFBP5 expression and overall survival of the AML patients. Both IGFBP5 overexpression and extrinsic rhIGFBP5 suppressed the growth of THP1 and U937 cells by inducing cell apoptosis and arresting G1/S transition and promoted the chemosensitivity of U937 and THP1 cells to daunorubicin and cytarabine. However, overexpression of mtIGFBP5 failed to demonstrate these properties. An in vivo xenograft mouse model of U937 cells also indicated that overexpression of IGFBP5 rather than mtIGFBP5 alleviated AML progression and extramedullary infiltration. Mechanistically, these biological consequences depended on the inactivation of insulin-like growth factor 1 receptor -mediated phosphatidylinositol-3-kinase/protein kinase B pathway. Conclusions: Our findings revealed secreted rather than intracellular IGFBP5 as a tumor-suppressor and chemosensitizer in AML. Upregulation of serum IGFBP5 by overexpression or addition of extrinsic rhIGFBP5 may serve as a suitable therapeutic approach for AML.

Interaction of Insulin-Like Growth Factor Binding Protein-3 with Latent Transforming Growth Factor-Beta Binding Protein-1

Insulin-like Growth Factor (Igf)-Binding Protein-3 (IGFBP-3) Binds to Fibronectin (FN): Demonstration of IGF-I/IGFBP-3/fn Ternary Complexes in Human Plasma.

Role of N- and C-terminal Residues of Insulin-like Growth Factor (Igf)-Binding Protein-3 in Regulating IGF Complex Formation and Receptor Activation*

Insulin-Like Growth Factor Binding Protein-2 Mediates The Inhibition Of Dna Synthesis By Transforming Growth Factor-Beta In Mink Lung Epithelial Cells

Insulin-Like Growth Factor (IGF) Binding Protein-3 Attenuates Prostate Tumor Growth by IGF-Dependent and IGF-Independent Mechanisms

Overexpression of Gly56/gly80/gly81-Mutant Insulin-Like Growth Factor-Binding Protein-3 in Transgenic Mice.

Igfbp, A Novel Target of Lung Cancer?

Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes.

Potential involvement of the interaction between insulin‐like growth factor binding protein (IGFBP)‐6 and LIM mineralization protein (LMP)‐1 in regulating osteoblast differentiation

IGFBP2 Function As a Novel Biomarker for Active Lupus Nephritis.

Impaired Glucose Homeostasis in Insulin-Like Growth Factor-Binding Protein-3-transgenic Mice.

Colocalization and Identification of Interaction Sites Between IGFBP-3 and GalNAc-T14

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-β signaling

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling.

IGFBP-3 Blocks Hyaluronan-CD44 Signaling, Leading to Increased Acetylcholinesterase Levels in A549 Cell Media and Apoptosis in a p53-Dependent Manner

Investigation of the Binding Network of IGF-I on the Cavity Surface of IGFBP4

Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix.

Insulin-like Growth Factor Factor Binding Protein-2 is a Novel Mediator of P53 Inhibition of Insulin-Like Growth Factor Signaling.

Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia

Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis

Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein.